オプションチェーンは、Bluejay Diagnosticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Bluejay Diagnosticsの市場センチメントを評価します。.

Bluejay Diagnostics (NASDAQ:BJDX) 株価情報, オプションチェーン

Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) could see significant workforce changes if California Governor Gavin Newsom proceeds with excluding the company from a proposed <a href="https://www.benzinga.com/tech/24/11/42183055/elon-musk-slams-californias-proposal-to-shut-tesla-evs-out-of-consumer-rebates-in-state-this-is-insane">electric vehicle consumer rebate program</a>, according to Dan Ives, analyst at Wedbush Securities.
What Happened: &#8220;You had Jake Paul and Tyson, and now you&#8217;ve got Newsom and Musk—this is gonna be battle,&#8221; Ives told Bloomberg in an interview. &#8220;It&#8217;s a political battle, but Tesla is the only EV manufacturer actually made in California.&#8221;
The analyst suggested that the proposed rebate program exclusion might accelerate job migrations from the company&#8217;s Fremont facility to its Texas headquarters.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dan Ives, senior equities analyst at Wedbush Securities talks about California Governor Gavin Newsom excluding Tesla&#39;s from a proposed consumer rebate program. Musk calls the proposal &quot;insane&quot; <a href="https://t.co/fetzLuxGOL">https://t.co/fetzLuxGOL</a> <a href="https://t.co/20oDaOLdb7">pic.twitter.com/20oDaOLdb7</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1861437239948939771?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Wedbush maintained its Outperform rating on Tesla shares, with a $400.00 price target, despite the brewing controversy, according <a href="https://in.investing.com/news/analyst-ratings/wedbush-sustains-tesla-stock-target-amid-ca-rebate-concerns-93CH-4546215">to</a> Investing.com. The firm&#8217;s commentary highlights the complex relationship between Tesla CEO Elon Musk and Newsom, which has been strained by previous disagreements, including COVID-related factory shutdowns and Tesla&#8217;s 2021 headquarters relocation.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a>
What Happened: Governor Newsom&#8217;s proposal aims to reinstate the state&#8217;s Clean Vehicle Rebate program, potentially excluding Tesla to promote market competition. This move comes in anticipation of potential federal EV tax credit eliminations.
Musk swiftly criticized the proposal, calling it &#8220;insane&#8221; and suggesting the decision could damage California&#8217;s economic interests. The dispute echoes ongoing <a href="https://www.benzinga.com/markets/equities/24/07/39815808/elon-musk-claps-back-after-gavin-newsom-shares-donald-trumps-drop-to-your-knees-and-beg-post-abo">tensions between Musk and Newsom</a>, including previous conflicts over state jobs and corporate taxation.
The potential rebate program exclusion could incentivize Tesla to accelerate job transfers from Fremont to its expanding Austin Gigafactory, a prospect Ives warned could significantly impact California&#8217;s manufacturing landscape.
Price Action: Tesla stock closed at $338.23 on Tuesday, down 0.11% for the day. In after-hours trading, the stock rose 0.57. Year-to-date, Tesla&#8217;s stock has surged by 36.15%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Fed Minutes Reveal &#8216;Confidence&#8217; In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead</a></li>
</ul>
Gavin Newsom Elon Musk &#x7C; Photos courtesy: Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

News

Global

Markets

TSLA

Dan Ives Compares Newsom Vs. Musk Battle To Jake Paul Vs. Tyson, Warns Of California's Job Migration Risk To Texas

Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) saw a significant drop of 10.71% in its stock price on Tuesday, closing at $3.50. After-hours trading showed a further decline of 4.57%. 
What Happened: This comes despite the company announcing the release of its new Battle Born smart lithium batteries with Dragonfly IntelLigence technology. 
The launch coincides with the Black Friday sales event, offering discounted prices through Cyber Monday. Dragonfly Energy&#8217;s batteries feature advanced monitoring capabilities, providing real-time data and alerts for enhanced system performance and compliance with industry standards.
DFLI is down 34.33% year-to-date, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DFLI

Dragonfly Energy Sees Over 10% Decline As New Smart Lithium Batteries Launch Amid Black Friday Event

LDTC

LeddarTech To Demonstrate Latest AI-Driven Automotive Software In Collaboration With Arm And Texas Instruments At CES 2025, Las Vegas

WIIM

DELL

Dell Technologies shares are trading lower after the company reported worse-than-expected Q3 sales results.

BTIG analyst Marie Thibault upgrades Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) from Neutral to Buy and announces $26 price target.

Upgrades

Price Target

Analyst Ratings

EMBC

BTIG Upgrades Embecta to Buy, Announces $26 Price Target

Jefferies analyst Omar Nokta maintains Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) with a Hold and lowers the price target from $12.5 to $12.

GOGL

Jefferies Maintains Hold on Golden Ocean Group, Lowers Price Target to $12

Benchmark analyst Fawne Jiang maintains H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) with a Buy and lowers the price target from $53 to $48.

HTHT

Benchmark Maintains Buy on H World Group, Lowers Price Target to $48

Shares of&nbsp;CrowdStrike Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dropped by 6.14% in pre-market trading on Wednesday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>. This decline followed a weaker-than-anticipated earnings forecast for the upcoming quarter, despite the company surpassing Wall Street estimates for the third quarter.
What Happened: CrowdStrike projected adjusted earnings of $0.84 to $0.86 per share for the fiscal fourth quarter, missing Wall Street&#8217;s expectation of $$0.86 cents per share. Despite this, the cybersecurity firm reported record revenue of $1.01 billion in the third quarter, exceeding the consensus estimate of $982.36 million. Adjusted earnings stood at $0.93 per share, surpassing analyst predictions of $0.81 per share.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154817/crypto-analyst-sees-shiba-inu-surging-more-than-2000-in-coming-rally?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Analyst Sees Shiba Inu Surging More Than 2,000% In Coming Rally</a>
The company&#8217;s recent performance follows a problematic <a href="https://www.benzinga.com/news/24/07/39870313/microsoft-crowdstrike-issue-caused-largest-it-outage-in-history-showing-how-much-we-depend-on-a-hand">software update in July </a>that caused global computer crashes. Investors have been closely monitoring&nbsp;CrowdStrike&nbsp;for signs of recovery since the incident. While the third-quarter results were strong, the cautious outlook for the upcoming quarter has tempered investor enthusiasm.
Meanwhile, post the earnings, Needham &amp; Company upgraded the price target from $360 to $420 while HSBC has downgraded to $347, as per <a href="https://pro.benzinga.com">Benzinga Pro</a> data.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CRWD/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27072909/Screenshot-2024-11-27-at-5.59.02%E2%80%AFPM-1024x394.png" alt="" class="wp-image-667216" /></a></figure>
Why It Matters: The recent earnings report highlights&nbsp;CrowdStrike&#8217;s&nbsp;ability to recover from the July software update fallout, which had significant global repercussions. The company has consistently <a href="https://www.benzinga.com/news/earnings/24/11/42202105/crowdstrike-beats-q3-earnings-revenue-estimates-cybersecurity-company-highlights-incredible-success-retaining-customers-following-it-outage">exceeded analyst estimates </a>since its public debut in 2019, showcasing resilience and strong customer retention.
Despite the technical challenges earlier in the year, CrowdStrike has<a href="https://www.benzinga.com/news/earnings/24/11/42209469/crowdstrike-stocks-technical-analysis-shows-bullish-trend-as-it-navigates-july-fallout-to-deliver-record-q3-revenue-heres-more"> demonstrated a bullish trend</a>. Despite falling in premarket trading on Wednesday, at $344 a piece, CrowdStrike's stock is above its 20, 50, and 200-day simple moving averages, suggesting a largely bullish trend.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Pre-Market Outlook

General

CRWD

CrowdStrike Shares Fall 6% Despite Beating Q3 Estimates: What's Going On?

Grant Cardone is getting vocal about housing. The real estate mogul and entrepreneur took to Twitter with strong words on the topic. &#8220;The average rate on a 30-year fixed mortgage is 6.84% this week,&#8221; <a href="https://x.com/GrantCardone/status/1859961992460816613">he tweeted,</a> citing Freddie Mac data. &#8220;The 7th weekly increase over the past eight weeks. If this continues, homeownership is OVER in America.&#8221;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
Bold claim? Yeah, but Cardone's not wrong about rates climbing fast. Mortgage rates have been creeping up for months. They're at levels not seen in over two decades. For context, the 30-year fixed mortgage rate averaged just 3% in 2021.. Today, it's more than double that. That spike is slamming potential homebuyers. Monthly payments are skyrocketing and dreams of owning a home feel like a pipe dream.
Cardone is known for his real estate empire and no-nonsense business advice. He has a long history of talking about housing. He's built his career around multifamily real estate. He also owns thousands of apartment units across the U.S. and has never been shy about saying <a href="https://www.benzinga.com/markets/24/11/42146196/homeownership-vs-renting-why-grant-cardone-thinks-the-american-dream-is-a-terrible-investment">homeownership isn't for everyone.</a> But this time, it's different. He's not just talking about the challenges of owning a home. He's saying rising rates could kill the American dream altogether.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
He didn't stop there. &#8220;America should have the best housing &amp; the lowest interest rates in the world,&#8221; he added. A big statement, but Cardone has a point. Higher rates don't just hurt buyers. They ripple through the entire economy. Housing is a massive driver of growth. When people can't buy, homebuilders stop building and industries like construction and home goods take a hit.
Cardone's tweet reflects the frustration of many. Rising rates are making housing <a href="https://www.benzinga.com/real-estate/24/10/41166593/grant-cardone-dispels-the-american-dream-of-homeownership-citing-mortgage-payments-as-double-the-ren">unaffordable for millions. </a>In 2021, the average 30-year fixed mortgage rate was 3%. A $300,000 mortgage at 3% costs around $1,265 a month. At today's rates? That same loan will set you back over $2,000. That's not chump change.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
This isn't just about numbers, either. For decades, homeownership has been a symbol of stability and success in America. But now, it's slipping further out of reach. Younger generations are especially hurting. Millennials and Gen Z, already burdened by student loans and rising living costs, are being hit the hardest.
The solution? That's up for debate. Some experts say the Federal Reserve needs to ease up on rate hikes. Others argue for more affordable housing options. Cardone's take? He didn't spell it out this time, but knowing him, he'd probably say it's time to think bigger and <a href="https://www.facebook.com/grantcardonefan/videos/invest-in-assets-that-produce-cash-flow/461800760050933/">focus on cash flow</a>. That could mean renting, investing or finding new ways to build wealth.
One thing's clear: If rates keep climbing, the housing market will keep feeling the heat. And for many, homeownership might be &#8220;OVER,&#8221; just like Cardone said.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Real Estate

Freddie Mac Reports 6.84% Mortgage Rate As Grant Cardone Warns Of Homeownership Crisis

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dip to $93,000 can be attributed to pressure from a combination of macroeconomic shifts, technical signals and on-chain trends, according to the latest note by 10x Research.
Despite this, the long-term outlook for 2025 appears optimistic, aligning with Bitcoin's historical cycles and broader economic trends, the analysts report.
The impact of rate cuts 
<ol>
<li></li>
</ol>
One of the primary drivers of Bitcoin's decline is the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Federal Reserve's cautious approach</a> to monetary easing.
"The FOMC minutes hint at a pause in monetary easing," the report notes, highlighting how this shift removes a critical tailwind that has historically supported Bitcoin's growth. 
Without the added boost from loose fiscal policies, Bitcoin has lost some of its upward momentum, exposing vulnerabilities in its price action.
Global liquidity taps start closing
Another factor impacting Bitcoin is its close correlation with <a href="https://www.benzinga.com/24/11/42170458/crude-oil-down-2-chicago-fed-national-activity-index-falls-in-october">global money supply changes</a>.
The report points out that "over the past 12 months, a clear correlation has emerged, with changes in money supply leading Bitcoin's movements by approximately ten weeks." 
This lagging effect has played out recently, as Bitcoin peaked in November following earlier monetary policy adjustments. 
However, with the pace of monetary expansion slowing, Bitcoin has struggled to maintain its previous trajectory.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42198909/trump-linked-crypto-platform-world-liberty-financial-appoints-justin-sun-as-advisor-after-30-million-investment">Trump-Linked Crypto Platform World Liberty Financial Appoints Justin Sun As Advisor After $30 Million Investment</a>
Technical indicators
<a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">Technical indicators</a> also reveal why Bitcoin's price has faltered.
According to the report, Bitcoin "confirmed bearish daily reversal signals in play, with weekly signals likely to follow," suggesting a potential correction from overbought levels. 
Analysts have identified critical support levels at $89,000 and $75,000, which will be key in determining whether Bitcoin can stabilize and regain momentum.
On-chain metrics offer additional context. 
The realized profit-loss ratio and changes in long-term holder positions have signaled increased selling pressure from experienced investors. 
The report notes, "A meaningful signal only emerges when this ratio reverses lower—indicating that longer-term holders are slowing their profitable coin sales."
This suggests that selling momentum could ease in the near future, paving the way for consolidation and eventual recovery.
What&#8217;s Next
Looking ahead, the report offers a cautiously optimistic view. 
While December has historically been a bullish month for Bitcoin, the broader outlook for 2025 remains the real focus. 
The report reinforces this sentiment, stating, "This pattern has consistently played out during Bitcoin&#8217;s short history, pointing to a continued bullish outlook for 2025." 
With cyclical trends and potential macroeconomic shifts aligning, Bitcoin may be poised for another strong performance in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">the years ahead</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin At $93,000—Crash Or Pause? 'Bullish Outlook For 2025,' Says 10x Research

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

ARWR

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $295 to $325.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $325

AMBA: 29% &#x7C; <a href="https://www.benzinga.com//node/42201842">Ambarella shares are trading higher after the company reported a year-over-year increase in Q3 revenue results.</a>
&nbsp;
TRNR: 86% &#x7C; <a href="https://www.benzinga.com//node/42210976">Interactive Strength Receives Letter Confirming Demonstrated Compliance With Nasdaq Listing Rule, Which Successfully Concludes Hearings Panel Appeal Process That Began In May</a>
&nbsp;
DELL: -13% &#x7C; <a href="https://www.benzinga.com//node/42201722">Dell Technologies shares are trading lower following a Q3 revenue miss.</a>

Movers

Trading Ideas

AMBA

TRNR

Market-Moving News for November 27th

Benchmark analyst Christopher Kuhn maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Buy and raises the price target from $32 to $34.

SNDR

Benchmark Maintains Buy on Schneider National, Raises Price Target to $34

Legendary investor&nbsp;Warren Buffett&nbsp;has a piece of critical advice for parents that he believes they should follow, regardless of their wealth status.
What Happened: In a recent letter, the Berkshire Hathaway CEO advised parents to not just write their will but also discuss it with their children.
"Be sure each child understands both the logic for your decisions and the responsibilities they will encounter upon your death," the Oracle of Omaha said.
This, Buffett says, essentially ensures that there is clarity about the inheritance between parents and their children, reducing the chances of disputes. This is especially important when parents are no longer there to resolve differences over matters such as these.
"If any have questions or suggestions, listen carefully and adopt those found sensible. You don't want your children asking ‘Why?' in respect to
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History'</a>
Buffett&#8217;s letter also recounted instances where families were torn apart due to unclear testamentary directives.
He encouraged parents to invite their adult children to discuss the will, ensuring transparency and understanding.
Why It Matters: This advice from Buffett aligns with his recent actions, including&nbsp;<a href="https://www.benzinga.com/news/24/11/42177867/warren-buffett-announces-new-charitable-gifts-updates-plans-for-150b-fortune-billionaire-wants-to-help-others-given-a-very-short-straw-at-birth">announcing new charitable donations</a>&nbsp;and updates to his $150 billion fortune.
Buffett has been converting Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shares to make these donations, emphasizing his commitment to philanthropy.
Buffett&#8217;s family dynamics also reflect his philosophy. His daughter-in-law, Mary Buffett, once thought she would receive &#8220;free candy&#8221; upon marrying his son, but learned there was no such thing with Warren, highlighting his emphasis on self-reliance and integrity.
This perspective is consistent with his hiring philosophy, where he values&nbsp;<a href="https://www.benzinga.com/startups/24/11/41976499/warren-buffett-shares-three-key-traits-to-look-for-when-hiring-says-that-without-integrity-the-other-two-will-kill-you">integrity above all</a>&nbsp;other traits.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42155884/economist-slams-doges-simplistic-approach-to-government-spending-questions-super-bowl-ad-criticism?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Economist Slams DOGE: Tells Elon Musk-Led Initiative To &#8216;Do Your Legal Job Well&#8217; Amid Super Bowl Ad Spending Clash</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Personal Finance

Warren Buffett Says Parents Should Do This One Thing Before They Die, Whether They Are Rich Or Not

Guidance

Symbotic Cuts Q1'FY25 Revenue Outlook From $495M - $515M To $480M - $500M (Est $503.579M)

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and maintains $385 price target.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Maintains $385 Price Target

As a result, gross profit, income (loss) before income tax, net income (loss) and adjusted EBITDA1 were also impacted. The company estimates the total impact of correcting these errors will be to lower system revenue, system gross profit, income (loss) before income tax, and adjusted EBITDA by $30 million to $40 million for fiscal year 2024 compared to the financial results released on November 18, 2024.

Symbotic Says Identified Errors In Its Revenue Recognition Related To Cost Overruns

Contracts

CAMT

Camtek Secures $50M In Pre-Launch Orders For New Hawk Product Ahead Of February 2025 Debut

CDRO

Codere Online Luxembourg Reports Q3 Revenues Of €49.2M Up From €41M YoY; Total Cash Position Of €44.0M As Of September 30

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) just reported results for the fourth quarter of 2023.<ul><li>Bluejay Diagnostics reported earnings per share of -$1.78. This was below the analyst estimate for EPS of -68 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/bjdx-stock-earnings-bluejay-diagnostics-for-q4-of-2023/">BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023

Bluejay Diagnostics (BJDX) has issued an announcement. Bluejay Diagnostics, Inc. has ended its agreement with DLA, LLC, leading to the departure of...

Bluejay Diagnostics Announces CFO Change and Stockholders' Meeting Date

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We are starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to read about!



Moving shares are earnings reports, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chicken Soup for the Soul (NASDAQ:<a href="https://investorplace.com/stock-quotes/csse-stock-quote/">CSSE</a>) stock is rocketing more than 68% alongside heavy pre-market trading.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) shares are soaring over 26% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318251841&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=84fce7fb704e6ef8a8fd234dc0d1a286&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-04-24">secondary offering news</a>.</li>



<li>GraniteShares 2x Long TSLA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLR#NASDAQ">TSLR</a>) stock is surging close to 24% following Tesla&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) <a href="https://www.marketwatch.com/livecoverage/tesla-earnings-ev-elon-musk-q1-stock-cybertruck-robotaxi/">latest earnings report</a>.</li>



<li>T-REX 2X Long Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslt-stock-quote/">TSLT</a>) shares are gaining more than 22% for the same reason. </li>



<li>Direxion Daily TSLA Bull 2X Shares (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsll-stock-quote/">TSLL</a>) stock is rising over 22% alongside TSLA earnings.</li>



<li>XBP Europe (NASDAQ:<a href="https://investorplace.com/stock-quotes/xbp-stock-quote/">XBP</a>) shares are increasing more than 22% without any clear news this morning.</li>



<li>B. Riley Financial (NASDAQ:<a href="https://investorplace.com/stock-quotes/rily-stock-quote/">RILY</a>) stock is climbing over 19% with the release of its <a href="https://www.prnewswire.com/news-releases/b-riley-financial-files-2023-annual-report-on-form-10-k-302125970.html">2023 annual report</a>.</li>



<li>Vertiv (NYSE:<a href="https://investorplace.com/stock-quotes/vrt-stock-quote/">VRT</a>) shares are heading more than 16% higher after <a href="https://www.investors.com/news/vertiv-spikes-on-earnings-ai-stocks-nvidia-super-micro/">releasing its Q1 earnings report</a>.</li>



<li>AudioEye (NASDAQ:<a href="https://investorplace.com/stock-quotes/aeye-stock-quote/">AEYE</a>) stock is getting an over 13% boost with its <a href="https://qz.com/audioeye-q1-earnings-snapshot-1851430210">Q1 earnings release</a>.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) shares are up more than 13% following a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318249494&amp;type=PDF&amp;symbol=WIMI&amp;cdn=21b188804ad8e2afae8ca53a0c6f207e&amp;companyName=WiMi+Hologram+Cloud+Inc.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-23">goodwill impairment assessment</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are plummeting more than 35% alongside its <a href="https://www.nasdaq.com/press-release/evotec-presents-fiscal-year-2023-results-and-announces-priority-reset-to-focus-on">latest earnings report</a>.</li>



<li>Fabrinet (NYSE:<a href="https://investorplace.com/stock-quotes/fn-stock-quote/">FN</a>) stock is diving over 24% after <a href="https://www.nasdaq.com/press-release/fabrinet-to-announce-third-quarter-fiscal-year-2024-financial-results-on-may-6-2024">announcing its earnings date</a>.</li>



<li>GraniteShares 2x Short TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsdd-stock-quote/">TSDD</a>) shares are dropping more than 23% after TSLA&rsquo;s earnings report.</li>



<li>T-Rex 2X Inverse Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslz-stock-quote/">TSLZ</a>) stock is falling over 23% for the same reason.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) shares are sliding 20% without any clear news.</li>



<li>Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) stock is decreasing more than 19% today.</li>



<li>Mawson Infrastructure (NASDAQ:<a href="https://investorplace.com/stock-quotes/migi-stock-quote/">MIGI</a>) shares are slipping nearly 16% on Wednesday morning.</li>



<li>Applied DNA Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apdn-stock-quote/">APDN</a>) stock is dipping over 15% ahead of a <a href="https://www.nasdaq.com/press-release/applied-dna-announces-1-for-20-reverse-stock-split-2024-04-22">reverse stock split tomorrow</a>.</li>



<li>BiomX (NYSEMKT:<a href="https://investorplace.com/stock-quotes/phge-stock-quote/">PHGE</a>) shares are declining more than 14% <a href="https://www.nasdaq.com/press-release/biomx-to-present-data-from-phase-1b-2a-study-of-bx004-for-the-treatment-of-cystic">following a rally yesterday</a>.</li>



<li>Ostin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ost-stock-quote/">OST</a>) stock closes out our pre-market stock movers down over 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders will want to read about on Monday morning!



Moving stocks this morning an investor update, clinical trial news, a private offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) stock is rocketing more than 69% alongside heavy pre-market trading.</li>



<li>Schmid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/">SHMD</a>) shares are soaring 40% without any clear news this morning.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging over 36% alongside an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318395592&amp;type=PDF&amp;symbol=NDRA&amp;cdn=4506ae3b1a739822361489bedc53ef84&amp;companyName=ENDRA+Life+Sciences+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-06-14">investor stake update</a>.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 21% with strong early morning trading.</li>



<li>Srivaru (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) stock is increasing over 18% as it continues to <a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">rally on e-bike news</a>.</li>



<li>Nurix Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrix-stock-quote/">NRIX</a>) shares are gaining 17% on <a href="https://www.marketwatch.com/story/nurix-therapeutics-shares-rise-on-positive-leukemia-drug-results-66b9d524?mod=investing">positive drug results</a>.</li>



<li>Icecure Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/">ICCM</a>) stock is getting a 14% boost with it still rallying on <a href="https://www.nasdaq.com/press-release/positive-data-icecures-kidney-cancer-clinical-study-presented-interventional">kidney cancer study data</a>.</li>



<li>Kineta (NASDAQ:<a href="https://investorplace.com/stock-quotes/ka-stock-quote/">KA</a>) shares are heading more than 13% higher with heavy trading today.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) stock is jumping over 12% this morning.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are up more than 11% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is plummeting more than 35% after a massive rally on Friday.</li>



<li>Sonim Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sonm-stock-quote/">SONM</a>) shares are diving over 25% this morning.</li>



<li>AMC Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/amcx-stock-quote/">AMCX</a>) stock is tumbling more than 23% after <a href="https://www.nasdaq.com/press-release/amc-networks-inc-announces-private-offering-125-million-convertible-senior-notes-2024">announcing a private offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) shares are taking an over 17% beating despite a lack of news.</li>



<li>Northann (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ncl-stock-quote/">NCL</a>) stock is falling close to 14% without any news to report.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are dropping more than 13% as it <a href="https://investorplace.com/2024/06/why-is-zapp-electric-vehicles-zapp-stock-up-173-today/">comes off a rally last week</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) stock is decreasing over 13% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396271&amp;type=PDF&amp;symbol=APVO&amp;cdn=21e6c068c48621c307f0f74bc8553007&amp;companyName=Aptevo+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-14">proposed public offering</a>.</li>



<li>Feutune Light Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/flfv-stock-quote/">FLFV</a>) shares are slipping almost 12% on Monday.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is dipping more than 11% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396398&amp;type=PDF&amp;symbol=VLCN&amp;cdn=980b1d9c3f018f25ac11de4d0e102b66&amp;companyName=Volcon+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-14">a delisting notice</a>.</li>



<li>Holdco Nuvo (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvo-stock-quote/">NUVO</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Bluejay Diagnostics announces 1-for-8 reverse stock split

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we dig into all of the news moving shares this morning!



Moving stocks are public offering updates, new investments an earnings report and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is rocketing more than 128% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417463&amp;type=PDF&amp;symbol=IONM&amp;cdn=8d8708e472ad2a1117d6e2e1ea234033&amp;companyName=Assure+Holdings+Corp.&amp;formType=RW&amp;formDescription=Registration+Withdrawal+Request&amp;dateFiled=2024-06-26">withdrawing a proposed public offering</a>.</li>



<li>Vigil Neuroscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/vigl-stock-quote/">VIGL</a>) shares are soaring over 40% on a <a href="https://www.globenewswire.com/news-release/2024/06/27/2904902/0/en/Vigil-Neuroscience-Announces-40-Million-Strategic-Investment-from-Sanofi.html">$40 million investment</a>.</li>



<li>CASI Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/casi-stock-quote/">CASI</a>) stock is surging more than 31% on a <a href="https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-15-million-private-placement-financing-by-venrock-healthcare-capital-partners-foresite-capital-panacea-venture-and-dr-wei-wu-he-302183230.html">$15 million private placement</a>.</li>



<li>Entero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ento-stock-quote/">ENTO</a>) shares are gaining over 26% on a <a href="https://www.nasdaq.com/press-release/entero-therapeutics-announces-peer-reviewed-publication-unveiling-novel-algorithm">peer-reviewed publication</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is increasing more than 24% as it <a href="https://investorplace.com/2024/06/faraday-future-ffie-stock-soars-80-following-rivian-volkswagen-deal/">continues a recent rally</a>.</li>



<li>Incannex Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/ixhl-stock-quote/">IXHL</a>) shares are jumping over 23% despite a lack of news this morning.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) stock is climbing more than 21% without any clear news this morning.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are heading close to 17% higher with heavy pre-market trading.</li>



<li>Phunware (NASDAQ:<a href="https://investorplace.com/stock-quotes/phun-stock-quote/">PHUN</a>) stock is getting an over 15% boost without any obvious news to report.</li>



<li>Hyzon Motors (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyzn-stock-quote/">HYZN</a>) shares are up nearly 15% with strong trading this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Branchout Food (NASDAQ:<a href="https://investorplace.com/stock-quotes/bof-stock-quote/">BOF</a>) stock is plummeting more than 37% after <a href="https://www.nasdaq.com/press-release/branchout-food-prices-14-million-follow-public-offering-2024-06-26">pricing a follow-on offering</a>.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving over 28% on a <a href="https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-d6yhuinwfxm9.html">proposed public offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) stock is tumbling more than 21% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318418078&amp;type=PDF&amp;symbol=BJDX&amp;cdn=14a15ef82de2ebc313ddbbf7cad3f31c&amp;companyName=Bluejay+Diagnostics+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-06-26">effecting a public offering</a>.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are taking an over 17% beating without any apparent news today.</li>



<li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is slipping more than 17% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417950&amp;type=PDF&amp;symbol=VSEE&amp;cdn=a8750adb0a7c7d12db86db6bfac8e49b&amp;companyName=VSee+Health+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-26">alongside recent insider trading</a>.</li>



<li>Swvl (NASDAQ:<a href="https://investorplace.com/stock-quotes/swvl-stock-quote/">SWVL</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Levi Strauss (NYSE:<a href="https://investorplace.com/stock-quotes/levi-stock-quote/">LEVI</a>) stock is decreasing more than 16% with its <a href="https://www.cnbc.com/2024/06/26/levi-levi-earnings-q2-2024.html">Q2 earnings report</a>.</li>



<li>International Paper (NYSE:<a href="https://investorplace.com/stock-quotes/ip-stock-quote/">IP</a>) shares are falling over 15% today.</li>



<li>Recursion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/">RXRX</a>) stock is slipping more than 14% after <a href="https://www.stocktitan.net/news/RXRX/recursion-announces-pricing-of-200-million-public-offering-of-class-49il22g17787.html">pricing a public offering</a>.</li>



<li>KraneShares California Carbon Allowance Strategy ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/kcca-stock-quote/">KCCA</a>) shares close out our pre-market stock movers down over 13%. </li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-27th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) just reported results for the second quarter of 2024.<ul><li>Bluejay Diagnostics reported earnings per share of -$5.12. This was below the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bjdx-stock-earnings-bluejay-diagnostics-for-q2-of-2024/">BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q2 2024

Bluejay Diagnostics announces 1 for 50 reverse stock split

Bluejay Diagnostics (BJDX) announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ra...

Bluejay Diagnostics announces 1-for-50 reverse stock split

19:50 EST Bluejay Diagnostics (BJDX) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Bluejay Diagnostics Inc trading halted, news pending

AEYE

AMCX

APDN

APVO

BJDX

CASI

CONN

CSSE

ENTO

FFIE

FLFV

GOVX

HYZN

ICCM

IMMP

IONM

IXHL

KAVL

KCCA

KPRX

LEVI

MAXN

MIGI

NDRA

NRIX

NUVO

PHGE

PHUN

RILY

RXRX

SCNI

SHMD

SONM

SVMH

SWVL

TNXP

TSDD

TSLL

TSLR

TSLT

TSLZ

VIGL

VINE

VLCN

VSEE

WIMI

XTLB

ZAPP

ZPTA

Press Releases

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Financing

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Reverse Stock Split

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Bitech Technologies (OTCQB: BTTC) Appoints Montgomery Bannerman to Drive Strategic Growth in Renewable Energy – see other stocks inside….

Comments

Bluejay Diagnostics

Bluejay Diagnostics (BJDX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル